We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Maxcyte Inc | MXCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 295.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 295.00 | 295.00 | 295.00 | 295.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 07/3/2024 12:05 by sebass I agree but they need something to be upbeat about. Guiding 3-5 SPL a year is not good enough. There is a lot of value in Biotech Maxcyte need to convince investors why they should park their cash with them. |
Posted at 05/10/2023 08:19 by adamb1978 I think its possibly just investor apathy 74tom. Not a problem for long-term holders at all though |
Posted at 10/8/2023 08:37 by adamb1978 Yes, but inevitable whilst revenues are low.They're fully cashed up for years to come so quarterly opex is largely irrelevant here. Not sure whether you joined the call last night but even if you are focussed on opex, they said they're still expecting the same burn rate this year. The value driver here is commercialisation of therapies from customers. If you look at the new slide in their investor deck, there's 8 of them planned for launch from 2025-7, so FDA approval 2024-26...so lots of consumables and milestone payments in that period, and then royalties following |
Posted at 09/8/2023 22:07 by adamb1978 Not great Q2 results, though given the Q1 results and commentary around them, these figures were never going to be great. Revenue down slightly year on year, though slightly up quarter on quarter. Guidance of flat yoy for 2023 is to be expected in that context, and good that they've maintained the $6m revenue for SPL payments.Still have bucket loads of cash but nice to hear that they're managing opex more closely so that even if revenue is lower than planned, they still hit the £400m end of year cash balance. There's a new slide in the investor presentation on their website (slide 15 I think) which shows timings for getting revenues from customer's therapies, and split into different waves. Helpful for thinking about how the royalties might increase. Main event this year remains the Vertex approval, which is hopefully coming in December... |
Posted at 11/5/2023 09:08 by adamb1978 Hi 2thedukeYes, its the way US companies report unfortunately. Very factual and limited commentary. Really need to listen to the Q&A part of earnings calls in order to get the colour Agree that the cash balance puts a floor under things. All small companies encounter bumps in the road. Thankfully this is bump in the road for MXCT won't be terminal - just annoying There's a couple new slides in their investor presentation on their website which gives comfort about the pipeline of treatments which its customers are developing Adam |
Posted at 24/3/2023 15:40 by thetrotsky Don't know about the rest of you but these days I just chuckle when companies say that they're looking at a US listing because US investors afford a higher valuation to biotechnology companies. I see Oxford Nanopore is just the latest to look across the Pond.Total baloney IMHO. The US market has moved on and biotechnology is no longer flavour of the month; it seems US investors are now just as capable of undervaluing companies as much as they were capable of overvaluing them in the past. Personally, I wouldn't complain if MXCT cancelled its US listing for all the "good" that it has done us. |
Posted at 15/3/2023 10:56 by nanopayments On shareholder dumping, 3X sales of 2000 shares on the LSE this morning. All other amounts are for sizes in double or triple digits. Tiny.On in vivo vs ex vivo, Doug Doerfler addressed this on the recent Cowen call. He said MaxCyte is a cell engineering company, not a Flow Electroporation company. Their field scientists work closely with partners and they want to be the first to know about competing delivery technology, so they can adopt it if appropriate. Beam Therapeutics is an important case study. They bought Guide for its LNP technology, so have every reason to push in vivo delivery, but continue to work with ex vivo (and MaxCyte) and continue to say it will remain an important technology for them. More generally, the markets have been extremely skittish recently. In the US, 2-year Treasury Bill yields dropped 100bps in 3 days starting the end of last week. The last time that happened was after the 1987 crash. Investors are redically reducing their duration. They want assets where cash flows are as close to the present as possible, not several years out. Who knows, maybe some of MaxCyte's partners were relying on funding from Silicon Valley Bank, but personally I suspect it more a case of risk-off trades taking centre stage that explain the drop in the stock price. Is there any reason to think the long-term drivers of growth have been permanently impaired? We are not even seeing management lower guidance for 2023. |
Posted at 08/3/2023 10:03 by adamb1978 Thanks for posting that nanopayments. Nice comments to see and agree that its undervalued. I think it probably falls beneath the radar of funds in teh US, whilst in the UK investors dont like this sort of company. It won't take much to get it moving through as a result |
Posted at 02/2/2023 18:06 by adamb1978 Thats a good find. Hadn't seen that. I guess a lot of investors might have missed it either, or assumed that if it really changed the investment case for MXCT then they would have RNS'd it |
Posted at 06/7/2021 11:07 by acuere This is the Telegraph article :-Questor: a ‘very special company’ about to list where investors will be besotted with it Questor share tip: MaxCyte offers huge potential but it may take a new listing on Nasdaq to get the share price higher still We can have no complaint about the performance of shares in MaxCyte, whose hi-tech machines help drugs firms make gene editing treatments: tipped at 370p in October last year, when we said they might be worth 500p, they closed last night at 886p and were as high as £10.40 in February. Normally we’d consider selling when a target price has been breached so comprehensively but MaxCyte finds itself in an anomalous position that it is about to rectify, a process that could do wonders for the share price. The company is based in America, has a roster of clients that are largely American and is the type of business that generates great enthusiasm among American investors – yet its shares trade on London’s Aim market. It would make far more sense to have a listing on the stock market favoured by its natural investors – the Nasdaq in New York – and the company is in the process of getting just such a listing. In the words of Richard Penny of Crux Asset Management, which owns a stake in MaxCyte, “investors in the US are besotted with gene editing – they are hugely buoyant about what they see as the third age of drug discovery” built on the decoding of the human genome 20 years ago. Besotted investors are in much shorter supply here. Britain may have a huge fund management industry but when it comes to the healthcare sector it lacks the critical mass in terms of specialist analysts, funds and brokers found in America. In fact, you could say we are positively hostile to healthcare start-ups at present. “Fire sales of the small biotech firms held in Neil Woodford’s funds depressed share prices and damaged sentiment across the board,” Mr Penny said. We can be much more confident about a Nasdaq listing now than we were when we mentioned the possibility last year. When the firm announced in February the raising of £40m from seven new and existing investors (all but one of them American, unsurprisingly) it said: “The financing will strengthen the company’s balance sheet as we continue to focus on accelerating revenue growth in 2021 and beyond, and marks a further important step towards our goal to dual-list on Nasdaq in 2021.” But there are positive developments to report from the business’s operations, too. Over the past year or so it has signed partnership agreements with four companies at the heart of what promises to be a whole new industry based on the “Crispr” gene editing tool, which won Nobel Prizes for chemistry for its inventors last year. The number of drugs being developed with the help of MaxCyte’s “electroporati As we said before, not all of them will work but we can expect a success rate of perhaps a third. Meanwhile the company makes money by selling or leasing its machines, from the sale of consumables and, in a few years’ time if all goes well, from royalties from successful treatments in which its technology was involved. Mr Penny acknowledged that “to some extent it requires the Nasdaq listing for the share price to remain high”. But he added: “MaxCyte is a very special company. Maybe it’s expensive for the London market but it’s cheap for the US. The potential here is not just a rise of 10pc or 20pc. And at a market value of almost $1bn it is only just coming on some investors’ radar.” |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
